InvestorsHub Logo
Followers 247
Posts 9363
Boards Moderated 5
Alias Born 07/30/2009

Re: pavlichen post# 47

Wednesday, 11/02/2011 5:15:17 PM

Wednesday, November 02, 2011 5:15:17 PM

Post# of 536
Compensated Awareness Post View Disclaimer
DD for $BSKS & Supera Group, LLC / From what I see 1500 shares of the 2000 traded on 11/01/2011 were either shorted or borrowed. BSKS Current Price is @$2.80, Barchart.com has next Support/Resistance Levels @$4.2500... Which happens to be the 4, 13 & 52 Week High.

20111101|BSKS|1500|0|2000|O

http://regsho.finra.org/FORFshvol20111101.txt
http://www.barchart.com/cheatsheet.php?sym=BSKS

In My Opinion ~

Market Makers are very low on BSKS shares available to the trading public, the shares they do have must be borrowed from each other to fill orders. Which I've concluded from Finra's regsho short interest data.

Supera Group, has created a perfect investment structure with a low float to launch Supera’s business models, servicing varies industries with their patented technology using high-capacity data storage in a card format.

I have not seen any better share structure on the market then BSKS... Have any of you?

If Supera Group has many of the patents to this "smart card" technology... Then I say $4.20 might not be the 4, 13 & 52 Week High... But more like the new 4, 13 & 52 Week Low!




What is a smart card?

Varies Industries and Common Applications:
Credit cards
Electronic cash
Computer security systems
Wireless communication
Loyalty systems (like frequent flyer points)
Banking
Satellite TV
Government identification

BSKS Current report filing (8-K)

Effective October 4, 2011, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Supera Group, LLC (“Supera”) pursuant to which Supera granted to the Company an exclusive license to use Supera’s technology, including patents for the manufacture and sale of readers/writers and high-capacity data storage in a card format for use in healthcare, patient management, medical, dental and pharmaceutical records and any other health application. In connection with entering into the License Agreement, the Company issued 30,200,000 shares to Supera and agreed to pay 4% of gross sales from licensed products. The term of the license grant is for until the last to expire of the Licensed Patents.

Item 3.02 Unregistered Sales of Equity Securities

Pursuant to the License Agreement, the Company issued to Supera an aggregate of 30,200,000 shares of its Common Stock (the “Shares”) of which 200,000 Shares were transferred to Duane Bennett for services rendered in connection with negotiating the License Agreement. The Shares were issued under an exemption from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof and Regulation D.

As a result of the issuance of the 30,200,000 shares and unrelated debt conversion issuances, the Company had 31,485,003 issued and outstanding shares of Common Stock as of the date hereof.

Unregistered Sales of Equity Securities
Effective October 20, 2011, the Company issued an aggregate of 8,050,000 shares (the “Shares”) of its Common Stock to four persons who are not affiliates of the Company. The Shares were issued pursuant to the conversion of the Company’s Convertible Promissory Note. The Shares were issued under an exemption from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof and Regulation D.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.